ClinicalTrials.Veeva

Menu
A

Arizona Clinical Research Center | Tucson, AZ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gemcitabine
Dexamethasone
Carboplatin
Paclitaxel
Leucovorin
Pixantrone
Oxaliplatin
Docetaxel
IPI-549
Elotuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 86 total trials

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab
Drug: Durvalumab

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), p...

Active, not recruiting
Non Small Cell Lung Cancer Metastatic
Sensitizing EGFR Gene Mutation
Drug: Zimberelimab
Drug: Etrumadenant

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Ph...

Enrolling
Locally Advanced or Metastatic Breast Cancer
Drug: LHRH Agonist
Drug: Phesgo

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REG...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: cemiplimab
Drug: Placebo

This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemothera...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: fianlimab

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in partic...

Active, not recruiting
Metastatic Colorectal Cancer
Drug: Regorafenib
Drug: m-FOLFOX-6 regimen

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol inv...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Dexamethasone

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patien...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Adagrasib

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in...

Enrolling
Extensive Stage Small Cell Lung Cancer
Drug: Serplulimab + chemotherapy (carboplatin-etoposide)
Drug: Atezolizumab + chemotherapy (carboplatin-etoposide)

Trial sponsors

CTI BioPharma logo
Arcus Biosciences logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
Sanofi logo
V
A
Astellas logo
Celgene logo
Exact Sciences Corporation logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems